- Home
- UBX vs BTAI Comparison
UBX vs BTAI Comparison
Compare UBX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- BTAI
- Stock Information
- Founded
- UBX 2009
- BTAI 2017
- Country
- UBX United States
- BTAI United States
- Employees
- UBX N/A
- BTAI N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- UBX Health Care
- BTAI Health Care
- Exchange
- UBX Nasdaq
- BTAI Nasdaq
- Market Cap
- UBX 24.6M
- BTAI 28.7M
- IPO Year
- UBX 2018
- BTAI 2018
- Fundamental
- Price
- UBX $1.00
- BTAI $0.36
- Analyst Decision
- UBX Strong Buy
- BTAI Strong Buy
- Analyst Count
- UBX 1
- BTAI 4
- Target Price
- UBX $8.00
- BTAI $5.00
- AVG Volume (30 Days)
- UBX 82.0K
- BTAI 949.6K
- Earning Date
- UBX 11-04-2024
- BTAI 11-14-2024
- Dividend Yield
- UBX N/A
- BTAI N/A
- EPS Growth
- UBX N/A
- BTAI N/A
- EPS
- UBX N/A
- BTAI N/A
- Revenue
- UBX N/A
- BTAI $2,276,000.00
- Revenue This Year
- UBX N/A
- BTAI $164.86
- Revenue Next Year
- UBX $33.62
- BTAI $69.74
- P/E Ratio
- UBX N/A
- BTAI N/A
- Revenue Growth
- UBX N/A
- BTAI 83.25
- 52 Week Low
- UBX $1.00
- BTAI $0.35
- 52 Week High
- UBX $2.02
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- UBX 28.85
- BTAI 32.49
- Support Level
- UBX $1.10
- BTAI $0.35
- Resistance Level
- UBX $1.23
- BTAI $0.52
- Average True Range (ATR)
- UBX 0.06
- BTAI 0.06
- MACD
- UBX -0.01
- BTAI -0.00
- Stochastic Oscillator
- UBX 0.00
- BTAI 2.92
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.